Article

Therapy-induced PSMA2 Sensitizes Prostate Cancer Cells to Residual Androgen and Promotes Neuroendocrine Lineage Transformation

2025-11-29

Abstract excerpt

<h4>ABSTRACT</h4> Aberrant activation of the androgen receptor (AR) pathway drives prostate cancer (PCa). Androgen deprivation therapy (ADT) and next-generation AR blockade (e.g., enzalutamide) are initially effective, but virtually all patients develop castration-resistant prostate cancer (CRPC), which frequently transitions to treatment-emergent neuroendocrine PCa (tNEPC) following AR suppression. The molecular...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 71be2397-0481-515d-8dc6-d1c2bc344cef
DOI: 10.1101/2025.11.25.690552

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Therapy-induced PSMA2 Sensitizes Prostate Cancer Cells to Residual Androgen and Promotes Neuroendocrine Lineage TransformationDOI 10.1101/2025.11.25.690552Read

Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independenceSemantic proximity Read

Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolutionSemantic proximity Read

Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression.Semantic proximity Read

Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progressionSemantic proximity Read

Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancerSemantic proximity Read

Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancerSemantic proximity Read

Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancerSemantic proximity Read

Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistanceSemantic proximity Read

Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived XenograftsSemantic proximity Read

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen IndependenceSemantic proximity Read

Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancerSemantic proximity Read

The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approachesSemantic proximity Read